Meningococcal Vaccines Market Size, Share, Growth Analysis, By Vaccine Type (Polysaccharide Vaccines, Conjugate Vaccines), By Brand (Menactra, Menveo), By Age Group (Infants, Children), By End User (Hospitals, Clinics), By Region - Industry Forecast 2025-2032

Global Meningococcal Vaccines Market size was valued at USD 4.30 billion in 2022 and is poised to grow from USD 4.58 billion in 2023 to USD 7.58 billion by 2031, growing at a CAGR of 6.5% during the forecast period (2024-2031).

The meningococcal vaccines market is highly competitive, with leading players focusing on innovation, strategic partnerships and market expansion to maintain their leadership. Leading companies engaged in research and development (R&D) to create vaccines extensive. For example, Serum has partnered with PATH-WHO to increase access to meningitis vaccines in Africa.  'Pfizer Inc. ', 'GlaxoSmithKline plc ', 'Sanofi S.A. ', 'Merck & Co., Inc. ', 'Novartis AG ', 'CSL Limited ', 'Serum Institute of India Pvt. Ltd. ', 'Biomed Pvt. Ltd. ', 'Bharat Biotech ', 'Biological E. Limited ', 'Hualan Biological Engineering Inc. ', 'Walvax Biotechnology Co., Ltd. ', 'Chongqing Zhifei Biological Products Co., Ltd. ', 'Emergent BioSolutions Inc. ', 'Incepta Vaccine Ltd. ', 'Panacea Biotec Ltd. ', 'LG Chem Ltd. ', 'Mitsubishi Tanabe Pharma Corporation ', 'Valneva SE ', 'Vaxart, Inc.', 'In March 2023, GSK plc achieved positive results for the MenABCWY combination vaccine candidate in a pivotal phase 3 clinical trial. In individuals aged 10-25 years, the vaccine will be administered as two doses.  ', 'In September 2022, Janssen Pharmaceuticals received FDA approval for its Meniquadfi meningococcal vaccine, which protects against four meningococcal disease serogroups. ', 'In May 2021, Bio-Manguinhos and Emergex (UK) signed the agreement. The agreement establishes a framework for future clinical trials, meningococcal vaccine development, COVID-19 vaccine development, sales and marketing and distribution within the Brazilian Ministry of National Health. '

One of the major drivers for the meningococcal vaccines market is the rising incidence of meningococcal diseases across the globe. Meningitis and septicemia due to Neisseria meningitis have high mortality and severe long-term effects, such as neurological damage, which leads health care providers to prioritize prevention through vaccination. Regions, especially Africa Sub-Saharan Africa, known as the "meningitis belts," reports widespread infection.  

Shift Toward Combination Vaccines: A notable meningococcal vaccines market trend is the increasing acceptance of combination vaccines that protect against multiple meningococcal strains. The demand for quadrivalent vaccines targeting serogroups A, C, W, and Y is increasingly preferred due to their broader coverage and reduced need for multiple doses. This shift addresses logistical challenges and improves immunization adherence, enhancing overall healthcare outcomes. 

As per meningococcal vaccines market outlook, North America dominated the overall market in terms of revenue in 2023 with a 57.0% share. Positive suggestions & support from governments and high R&D investme5nts are some of the factors driving the North America region. Furthermore, improved healthcare infrastructure and awareness campaigns within the sector are expected to propel market growth. Marketers are also actively involved in awareness campaigns to increase uptake of meningococcal vaccine in the region. For example, in August 2021, GSK plc. launched the ASK2BSure campaign to encourage parents to visit doctors for meningitis B vaccination for their children.